|  Keyword Search
| Date | Title | | | 11/13/08 | MDRNA, Inc. Announces Third Quarter 2008 Financial Results| BOTHELL, WA, Nov 13, 2008 (MARKET WIRE via COMTEX News Network) -- MDRNA, Inc. (NASDAQ: MRNA) today reported financial results for the
three- and nine-month periods ended September 30, 2008.
Revenue for the three months ended September 30, 2008 was $0.4
million, compared to $1.9 million for the three months ended September
30, 2007. Revenue for the nine months ended September 30, 2008 was
$2.4 million, compared to $11.7 million for the nine months ended
September 30, 2007. Revenue in 2008 ... |
|  | | 11/06/08 | MDRNA, Inc. to Hold Third Quarter 2008 Earnings Conference Call on Thursday, November 13, 2008, at 4:30 p.m. Eastern Time| BOTHELL, WA, Nov 06, 2008 (MARKET WIRE via COMTEX News Network) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it will host a
conference call with investors and security analysts on Thursday,
November 13, 2008, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)
to discuss financial results for the third quarter ended September
30, 2008. To participate in the live conference call, U.S. residents
should dial 800-573-4754 and international callers should dial
617-224-4325. The participant... |
| | | 10/28/08 | MDRNA, Inc. Appoints Barry Polisky, Ph.D., as Chief Scientific Officer| Names New Chairman of the Board and Chair of the Scientific Advisory BoardBOTHELL, WA, Oct 28, 2008 (MARKET WIRE via COMTEX News Network) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that Barry Polisky,
Ph.D., will join the Company as Chief Scientific Officer on January
2, 2009. Dr. Polisky replaces Steven C. Quay, M.D., Ph.D., Chief
Scientific Officer, Chairman of the Board of Directors and Chairman
of the Scientific Advisory Board, who will be leaving the Company on
November 30, 2008. Dr... |
| | | 10/22/08 | MDRNA, Inc. Acquires Patent Estate to Broaden Its RNAi Intellectual Property Portfolio| Acquires Rights to UNA Technology for Proprietary Stabilization of Both RISC and Dicer siRNAsBOTHELL, WA, Oct 22, 2008 (MARKET WIRE via COMTEX News Network) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it has acquired
intellectual property related to non-nucleotide chemistry (Unlocked
Nucleic Acid) technology from RiboTask ApS, a privately held Danish
company specializing in the development and synthesis of novel RNA
chemistries. The technology will permit MDRNA to stabilize and
provi... |
| | | 10/07/08 | MDRNA, Inc. Advances RNAi Pipeline With Selection of Lead Candidate for Hypercholesterolemia Program| MDR-04227 Is a Dicer Substrate siRNA Targeting Apolipoprotein B (ApoB)BOTHELL, WA, Oct 07, 2008 (MARKET WIRE via COMTEX News Network) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that it has advanced its
RNAi pipeline with the selection of a Lead Candidate in its
hypercholesterolemia program targeting Apolipoprotein B (ApoB). The
compound, designated MDR-04227, was developed using MDRNA's propriety
drug discovery engine, which is built on a broad and enabling
intellectual property estate a... |
| | | 09/25/08 | MDRNA, Inc. Receives NASDAQ Notice Letter| BOTHELL, WA, Sep 25, 2008 (MARKET WIRE via COMTEX News Network) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that on September 19,
2008, it received a notification letter from the Listing
Qualifications Department of the NASDAQ Stock Market. The notice, in
accordance with NASDAQ Marketplace Rule 4450(a)(5) "Minimum Bid Price
Requirement," states that the Company's common stock has closed below
$1.00 per share for 30 consecutive business days. This notification
has no immediate effect on t... |
| | | 09/23/08 | MDRNA, Inc. to Present at the Maxim Group Growth Conference| BOTHELL, WA, Sep 23, 2008 (MARKET WIRE via COMTEX News Network) -- MDRNA, Inc. (NASDAQ: MRNA) announced today that J. Michael French,
CEO, will present at the Maxim Group Growth Conference on Tuesday,
October 7, 2008, at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time)
at the Grand Hyatt Hotel in New York City.
"We appreciate the opportunity to present the growing investment
opportunity at MDRNA to security analysts, fund managers and
institutional investors at the Maxim Group Growth Confe... |
| | | 09/15/08 | J. Michael French, CEO of MDRNA, Inc., Appointed to Board of Directors and Will Become President Effective October 1, 2008| BOTHELL, Wash.--(BUSINESS WIRE)--Sept. 15, 2008--MDRNA, Inc.
(Nasdaq: MRNA) announced today that J. Michael French, CEO, has been
appointed to the Company's Board of Directors. Mr. French, 48, will
also assume the additional role of President effective October 1,
2008.
"On behalf of the Board of Directors, I am pleased to welcome
Michael to MDRNA's Board," stated Bruce R. Thaw, Lead Independent
Director of MDRNA. "Since joining the Company as CEO in June, Michael
has demonstrated... |
| | | 09/04/08 | MDRNA Receives Additional Funding from National Institutes of Health| - Five Year Grant Continues Funding Research in RNAi Inhibition of
Influenza -
BOTHELL, Wash.--(BUSINESS WIRE)--Sept. 4, 2008--MDRNA, Inc.
(Nasdaq: MRNA) announced today that the National Institutes of Health
(NIH) has awarded the Company over $350,000 for further development of
the Company's siRNA therapeutics program to prevent and treat
influenza. These funds are part of a five-year grant totaling $1.9
million that the NIH awarded the Company in Septe... |
| | | 08/19/08 | MDRNA, Inc. Completes Exclusive License Agreement to RNAi Delivery Peptides| - Novel Cationic Peptides from University of Michigan improve
siRNA delivery -
BOTHELL, Wash.--(BUSINESS WIRE)--Aug. 19, 2008--MDRNA, Inc.
(Nasdaq: MRNA) announced today that it has signed an exclusive license
agreement to intellectual property from the University of Michigan
covering cationic peptides for enhanced delivery of nucleic acids.
Terms of the agreement were not disclosed.
"The University of Michigan peptides have unique characteristics
t... |
| | | 08/13/08 | MDRNA, Inc. Lead Candidate Demonstrates In Vivo Efficacy against Seasonal and Pandemic Flu Strains| - Intranasal administration of an siRNA in a proprietary delivery
system produces greater than 99% reduction in viral titers and a 100%
survival benefit against Avian Flu -
BOTHELL, Wash.--(BUSINESS WIRE)--Aug. 13, 2008--MDRNA, Inc.
(Nasdaq: MRNA) announced today positive in vivo efficacy data on its
proprietary RNAi-based therapeutic for the treatment of multiple
strains of influenza A virus in animal models. The in vivo data were
presented by Shaguna Seth, Ph.D., Associ... |
| | | 08/04/08 | MDRNA, Inc. Announces Second Quarter 2008 Financial Results and Additional Corporate Restructuring| BOTHELL, Wash.--(BUSINESS WIRE)--Aug. 4, 2008--MDRNA, Inc.
(Nasdaq: MRNA) today reported financial results for the three- and
six-month periods ended June 30, 2008, and a further corporate
restructuring.
Revenue for the three months ended June 30, 2008, was $0.7
million, compared to $4.9 million for the three months ended June 30,
2007. Revenue for the six months ended June 30, 2008 was $2.0 million,
compared to $9.9 million for the six months ended June 30, 2007.
Revenue in 2008... |
| | | 08/01/08 | MDRNA, Inc. Demonstrates In Vivo Efficacy with Proprietary DiLA2 Delivery Platform| Systemic delivery of 3-stranded siRNA constructs formulated in
proprietary liposomes decreases serum cholesterol
BOTHELL, Wash.--(BUSINESS WIRE)--Aug. 1, 2008--MDRNA, Inc.
(Nasdaq: MRNA) announced today positive in vivo efficacy data using a
novel combination of a meroduplex siRNA and MDRNA's proprietary
lipid-based delivery platform, the DiLA2 Platform. The data presented
today by Narendra Vaish, Ph.D., MBA, Senior Research Scientist and
Group Leader - RNAi Platform Te... |
| | | 07/31/08 | MDRNA Announces Phase 2 Trial of PYY(3-36) Does not Meet Weight Loss Endpoint| - Data demonstrate effective delivery of PYY -
BOTHELL, Wash.--(BUSINESS WIRE)--July 31, 2008--MDRNA, Inc.
(Nasdaq: MRNA) announced today results from a Phase 2 clinical trial
evaluating PYY(3-36) Nasal Spray (PYY) for the treatment of obesity.
The data indicate that PYY did not meet the primary efficacy endpoint
of a dose response of weight loss vs. PYY dose, nor did PYY meet the
secondary efficacy endpoint of greater weight loss than the active
control, sibutramine (Meridia(R)).... |
| | | 07/28/08 | MDRNA, Inc. to Hold Second Quarter 2008 Earnings Conference on Monday, August 4, 2008, at 4:30 p.m. Eastern Time| BOTHELL, Wash.--(BUSINESS WIRE)--July 28, 2008--MDRNA, Inc.
(Nasdaq: MRNA) announced today that it will host a conference call
with investors and security analysts on Monday, August 4, 2008, at
4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss financial
results for the second quarter ended June 30, 2008. To participate in
the live conference call, U.S. residents should dial 866-825-3354 and
international callers should dial 617-213-8063. The participant code
for the live conf... |
| | | 07/28/08 | MDRNA, Inc. to Present at BMO Capital Markets 2008 Focus on Healthcare Conference| BOTHELL, Wash.--(BUSINESS WIRE)--July 28, 2008--MDRNA, Inc.
(Nasdaq: MRNA) announced today that it will present at the BMO Capital
Markets Focus on Healthcare Conference on Wednesday, August 6, 2008,
at 11:15 a.m. Eastern Time (8:15 a.m. Pacific Time) at the Millennium
Broadway Hotel in New York City.
To access the live audio webcast for this conference, please log
on to MDRNA's Web site at http://www.mdrnainc.com approximately 15
minutes prior to the presentation in order to regi... |
| | | 06/23/08 | MDRNA, Inc. Announces Option Grant to Its Chief Executive Officer under NASDAQ Marketplace Rule 4350| BOTHELL, Wash.--(BUSINESS WIRE)--June 23, 2008--MDRNA, Inc.
(Nasdaq: MRNA) announced today that in accordance with NASDAQ
Marketplace Rule 4350(i)(1)(A)(iv), the Compensation Committee of the
Board of Directors approved an inducement grant of stock options to J.
Michael French, MDRNA's Chief Executive Officer, in connection with
the employment agreement that MDRNA entered into with Mr. French. On
June 23, 2008, Mr. French was granted options to purchase up to
1,260,000 shares of Commo... |
| | | 06/10/08 | Nastech Initiates New Corporate Direction with Name Change to MDRNA, Inc. and Appointment of J. Michael French as Chief Executive Officer| BOTHELL, Wash.--(BUSINESS WIRE)--Nastech Pharmaceutical Company Inc. (Nasdaq:
NSTK - News) announced that having acquired shareholder approval, effective
today the Company has changed its name to MDRNA, Inc. (“MDRNA”). MDRNA will
leverage its scientific and intellectual property (IP) position surrounding
the research, development and delivery of Dicer substrates and “Meroduplex”
(mdRNA) RNA interference (RNAi) drug candidates to build an industry-leading
position in the d... |
| | | 06/09/08 | Nastech Announces Positive Intranasal Insulin Data at American Diabetes Association Meeting| - Ultra rapid acting intranasal insulin offers mealtime glucose
control with significantly reduced risk of hypoglycemia -
BOTHELL, Wash.--(BUSINESS WIRE)--June 9, 2008--Nastech
Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today data from a
Phase II clinical trial demonstrating that its ultra rapid acting
intranasal insulin was both superior to usual therapy (oral
anti-diabetic medicines and/or basal insulin) and non-inferior to
insulin aspart (NovoLog(R)), a rap... |
| | | 05/08/08 | Nastech Announces First Quarter 2008 Financial Results| BOTHELL, Wash.--(BUSINESS WIRE)--May 8, 2008--Nastech
Pharmaceutical Company Inc. (Nasdaq: NSTK) today reported financial
results for the quarter ended March 31, 2008.
Revenue for the three months ended March 31, 2008, was $1.3
million, compared to $5.0 million for the three months ended March 31,
2007. The 2008 period included $0.1 million in government grant
revenue and $0.5 million in Nascobal(R) product sales. The $0.7
million in license and research fee revenue was primaril... |
| | | 05/01/08 | Nastech to Release First Quarter Financial Results and Host Webcast on Thursday, May 8, 2008| BOTHELL, Wash.--(BUSINESS WIRE)--May 1, 2008--Nastech
Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that its
first quarter financial results will be released on Thursday, May 8,
2008, at 4:00 p.m. Eastern Time (1:00 p.m. Pacific Time). Management
will then host a conference call beginning at 4:30 p.m. Eastern Time
(1:30 p.m. Pacific Time) to discuss first quarter financial results
and provide a corporate update.
To participate in the live conference call, U.S. residen... |
| | | 04/25/08 | Nastech Pharmaceutical Company Inc. Raises $7.93 Million in Registered Direct Offering| BOTHELL, Wash.--(BUSINESS WIRE)--April 25, 2008--Nastech
Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that it has
entered into definitive agreements with new and existing investors to
raise gross proceeds of $7,932,500 though a registered direct
offering. Under terms of the agreement, the Company will sell
4,585,260 shares of its common stock at $1.73 per share. As part of
the transaction, the investors also will receive warrants, with a
7-year term, to purchase 4,585,26... |
| | | 03/27/08 | Nastech Pharmaceutical Company Inc. Announces Appointment of Gunter Blobel, M.D., Ph.D., to its MDRNA, Inc. Scientific Advisory Board| BOTHELL, Wash.--(BUSINESS WIRE)--March 27, 2008--Nastech
Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that Gunter
Blobel, M.D., Ph.D., has joined the Scientific Advisory Board of
MDRNA, Inc., Nastech's wholly-owned subsidiary for the development of
RNAi technology and therapeutics. Dr. Blobel is a Howard Hughes
Medical Institute investigator at The Rockefeller University in New
York City. In 1999, Dr. Blobel was awarded the Nobel Prize in
Physiology or Medicine for his w... |
| | | 03/25/08 | Nastech Pharmaceutical Company Inc. to Present RNAi Data| BOTHELL, Wash.--(BUSINESS WIRE)--March 25, 2008--Nastech
Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that
Narendra Vaish, Ph.D., MBA, Senior Research Scientist and Group Leader
- RNAi Platform Technologies, will present a poster titled: RNAi
Activity from siRNA Duplexes Containing Nicks or Gaps in the Passenger
Strand, at the Keystone Symposia's RNAi, MicroRNA, and Non-coding RNA
meeting, on Saturday, March 29, 2008.
"We are pleased to have the opportunity to presen... |
| | | 03/21/08 | Nastech Pharmaceutical Company Inc. Complies with Nasdaq Marketplace Rule 4350(b)(1)(B)| BOTHELL, Wash.--(BUSINESS WIRE)--March 21, 2008--Nastech
Pharmaceutical Company Inc. (Nasdaq: NSTK), in compliance with Nasdaq
Marketplace Rule 4350(b)(1)(B), which requires separate disclosure of
receipt of an audit opinion that contains a going concern
qualification, disclosed that our Annual Report (Form 10-K) for the
year ended December 31, 2007 contains a going concern qualification
from our independent registered public accounting firm, KPMG LLP.
This announcement does not... |
| | | 03/17/08 | Nastech Announces Fourth Quarter and Full Year 2007 Financial Results| BOTHELL, Wash.--(BUSINESS WIRE)--March 17, 2008--Nastech
Pharmaceutical Company Inc. (Nasdaq: NSTK) today reported financial
results for the fourth quarter and year ended December 31, 2007.
Revenue for the three months ended December 31, 2007 was $6.4
million, compared to $4.8 million for the quarter ended December 31,
2006. The fourth quarter 2007 period included recognition of
approximately $5.5 million in previously deferred revenue related to
our Parathyroid Hormone (PTH1-34) ... |
| | | 03/13/08 | Nastech Pharmaceutical Company Inc. to Present at the Invest Northwest CEO & Investor Forum| BOTHELL, Wash.--(BUSINESS WIRE)--March 13, 2008--Nastech
Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that it
will present at the Invest Northwest CEO & Investor Forum on Tuesday,
March 18, 2008, at 4:30 p.m. Pacific Time at the Bell Harbor
International Conference Center in Seattle, Washington.
To access the live audio webcast for this conference, please log
on to Nastech's Web site at http://www.nastech.com approximately 15
minutes prior to the presentation in orde... |
| | | 03/11/08 | Nastech Pharmaceutical Company Inc. Completes Key RNAi Patent Filings| Conference call at 4:15 pm Eastern time (1:15 pm Pacific time)
today
BOTHELL, Wash.--(BUSINESS WIRE)--March 11, 2008--Nastech
Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that it has
completed filing 83 patent applications (79 international applications
and 4 U.S. applications) directed toward 144 different genes with
siRNA's designed and modified using Nastech's proprietary RNAi
technologies. These gene targets are disease-validated ... |
| | | 03/07/08 | Nastech Pharmaceutical Company Inc. Announces Scientific Advisory Board for MDRNA, Inc., its Wholly-Owned RNAi Subsidiary| BOTHELL, Wash., Mar 07, 2008 (BUSINESS WIRE) -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today
the appointment of a Scientific Advisory Board (SAB) for MDRNA, Inc.,
its wholly-owned subsidiary for the development of RNAi technology and
therapeutics. The SAB, initially comprised of three noted scientists
and clinicians, will provide critical scientific and medical input on
MDRNA's strategic direction.
"The formation of such a strong Scientific Advisory Board speaks
to o... |
| | | 02/29/08 | Nastech Pharmaceutical Company Inc. to Hold Conference Call to Discuss Corporate Restructuring and Future Strategy on Monday, March 3, 2008| BOTHELL, Wash., Feb 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it will host a conference
call with investors and security analysts on Monday, March 3, 2008, at 11:30
a.m. Eastern time (8:30 a.m. Pacific time) to discuss the Company's corporate
restructuring initiatives and future strategy. To participate in the live
conference call, U.S. residents should dial (800) 901-5259 and international
callers sho... |
| | | 02/12/08 | Nastech Pharmaceutical Company Implements Additional Workforce Reduction as Part of Previously Announced Corporate Restructuring| BOTHELL, Wash., Feb. 12 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that its Board of Directors has
approved a plan to further reduce operating expenses and align the company's
workforce with its strategic, business and clinical development requirements.
"The workforce reduction of approximately 50 employees will enable us to
drive our key clinical development and RNAi programs forward in a more
efficient manner for the benefit of ... |
| | | 02/05/08 | Nastech Appoints MDRNA, Inc. Directors Strategic Advisory Board| BOTHELL, Wash., Feb. 5 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. ("Nastech") (Nasdaq: NSTK) announced today that it has named
members to the MDRNA, Inc. ("MDRNA") Directors Strategic Advisory Board that
will provide scientific, financial and corporate governance expertise as
Nastech moves to establish MDRNA, currently a wholly-owned subsidiary, as an
independent company.
Advisory Board appointees include:
Susan B. Bayh, J.D. has been a director of Nastech s... |
| | | 01/08/08 | Nastech Completes Enrollment of Phase 2 Clinical Trial of PYY3-36 Nasal Spray to Treat Obesity| BOTHELL, Wash., Jan 08, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced the completion of enrollment for its
Phase 2 clinical trial of PYY3-36 Nasal Spray to treat obesity. The Company
enrolled 551 obese patients at multiple clinical sites in the United States
for a six-month, randomized, placebo-controlled dose ranging study. The study
is designed to evaluate three different doses of PYY3-36 Nasal Spray compared
to placeb... |
| | | 01/08/08 | Nastech Receives Notice of Allowance for U.S. Patent Related to Methods for Identifying Cell-Specific Targeting Peptides| BOTHELL, Wash., Jan 08, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that the U.S. Patent and Trademark
Office (USPTO) has issued a Notice of Allowance for U.S. patent application
No. 10/976,942, entitled "Phage Displayed Trp Cage Ligands." The patent
application has claims that relate to a novel, high-throughput method for
identifying peptides which can bind to specific cell types.
"A major obstacle in the develo... |
| | | 01/07/08 | Nastech Appoints Bruce R. York as Interim Chief Financial Officer| BOTHELL, Wash., Jan. 7 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced the appointment of Bruce R. York to the
position of Secretary and interim Chief Financial Officer, effective January
4, 2008. Mr. York will replace Philip C. Ranker, who resigned as Chief
Financial Officer and Secretary of Nastech effective January 4, 2008.
Mr. York has held senior financial positions at a number of biotechnology
and technology companies during his nearly ... |
| | | 12/20/07 | Nastech Announces Promotion of Gordon Brandt, M.D. to President| BOTHELL, Wash., Dec. 20 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it has promoted Gordon
Brandt, M.D. to President of Nastech. Dr. Brandt previously held the title of
Executive Vice President, Clinical Research and Medical Affairs. Dr. Steven
Quay will remain the Company's Chairman and Chief Executive Officer.
"We are pleased to promote Gordon to the position of President of Nastech
as he has been instrumental in progressing o... |
| | | 12/18/07 | Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.| Assignment of over 100 RNA-related Inventions
a Key Step in Establishing MDRNA as an Independent Company
BOTHELL, Wash., Dec. 18 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. ("Nastech") (Nasdaq: NSTK) announced today that it has assigned
(i) certain Nastech licenses to third-party intellectual property and (ii)
Nastech's own intellectual property, as such intellectual property relates to
the development of RNA-based therapeutics, to its subsidiary, MD... |
| | | 12/05/07 | Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding| BOTHELL, Wash., Dec. 5 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that they have entered into a
feasibility study with an undisclosed global leader in the production of
plasma products, to develop an alternative dosage form of Factor IX protein
which is currently administered by injection to control and prevent bleeding
in patients with hemophilia B.
"We look forward to working with our new global partner to evaluate the
feasibilit... |
| | | 11/27/07 | Nastech to Present at BMO Capital Markets Focus on Healthcare Conference| BOTHELL, Wash., Nov. 27 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it will present at the BMO
Capital Markets Focus on Healthcare Conference on Wednesday, December 5, 2007
at 2:00 p.m. Eastern Time at the Millennium Broadway Hotel in New York City.
To access the live audio webcast for this conference, please log on to
Nastech's website at http://www.nastech.com approximately 15 minutes prior to
the presentation in order to regi... |
| | | 11/13/07 | Nastech Pharmaceutical Company Initiates Plan for Corporate Restructuring and Will Concentrate on Phase 2 Clinical Programs| Company to Host Webcast and Conference Call
BOTHELL, Wash., Nov. 13 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. ("Nastech") (Nasdaq: NSTK) announced today its corporate
restructuring initiatives aimed at reducing operating expenses and enhancing
shareholder value. Nastech will seek to establish its subsidiary, MDRNA, Inc.,
as an independent, separately financed company as was announced today, and
will concentrate on Phase 2 clinical and partnered programs as... |
| | | 11/13/07 | Nastech to Establish Subsidiary, MDRNA, Inc., as an Independent Company to Focus on the Development of RNA-Based Therapeutics| BOTHELL, Wash., Nov. 13 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. ("Nastech") (Nasdaq: NSTK) announced today that the Board of
Directors has approved the recommendation of its Special Committee to move
forward with the process of establishing Nastech's wholly-owned subsidiary,
MDRNA, Inc. ("MDRNA"), as an independent company. Nastech is transferring its
intellectual property and agreements related to RNA interference ("RNAi") into
MDRNA. The new structure will give... |
| | | 11/07/07 | Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble| Company Will Advance Product into Phase 2 Bone Mineral Density Study in 1Q08
BOTHELL, Wash., Nov. 7 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it has reacquired the rights
to teriparatide (Parathyroid Hormone; PTH1-34) nasal spray for the treatment
of osteoporosis from its collaboration partner, Procter & Gamble
Pharmaceuticals, Inc. The reacquisition follows notification on Nov. 6, 2007,
of Procter & Gamble's decision to terminat... |
| | | 10/31/07 | Nastech to Present at Acumen BioFin Rodman & Renshaw Healthcare Conference| BOTHELL, Wash., Oct. 31 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it will present at the Acumen
BioFin Rodman & Renshaw Healthcare Conference on Monday, November 5, 2007 at
2:40 p.m. Eastern Time at the New York Palace Hotel in New York City.
To access the live audio webcast for this conference, please log on to
Nastech's website at http://www.nastech.com approximately 15 minutes prior to
the presentation in order to register ... |
| | | 10/29/07 | Nastech Announces Third Quarter 2007 Financial Results| BOTHELL, Wash., Oct. 29 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today reported financial results for the
three- and nine-month periods ended September 30, 2007.
Revenue for the quarter ended September 30, 2007 was $1.9 million,
compared to $5.5 million for the quarter ended September 30, 2006. The 2006
period included revenue of $4.8 million related to our Parathyroid Hormone
(PTH1-34) nasal spray collaboration with Procter & Gamble Pharmaceuti... |
| | | 10/22/07 | Nastech to Release Third Quarter Financial Results and Host Webcast on Monday, October 29, 2007| BOTHELL, Wash., Oct. 22 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that its third quarter financial
results will be released on Monday, October 29, 2007. Management will host a
conference call with investors and financial analysts to discuss these results
and to provide an update of the Company's clinical pipeline at 4:30 p.m.
Eastern Time (1:30 p.m. Pacific Time).
To participate in the live conference call, U.S. residents should di... |
| | | 10/05/07 | Nastech Pharmaceutical Company Announces the Jeffrey Wenig Memorial Award for Outstanding Achievement in Drug Delivery| BOTHELL, Wash., Oct. 5 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), a leader in molecular-biology based drug delivery
technology, announced today the establishment of the Jeffrey Wenig Memorial
Award for Outstanding Achievement in Drug Delivery, and its first recipients,
Dr. Robert S. Langer of the Massachusetts Institute of Technology and Dr. Paul
H. Johnson of Nastech.
"Cutting edge drug delivery technologies are critical to the development
and s... |
| | | 10/04/07 | Nastech Pharmaceutical Company Announces Promotion of Rick Costantino, Ph.D., to Chief Scientific Officer of Delivery| BOTHELL, Wash., Oct. 4 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today the promotion of Henry "Rick"
Costantino, Ph.D., to Chief Scientific Officer of Delivery. Dr. Costantino
will assume the responsibilities for leading Nastech's development of new drug
delivery technologies for peptide and protein therapeutics. Paul Johnson,
Ph.D., Nastech's Chief Scientific Officer since 2003, is retiring tomorrow,
October 5, 2007, as was previously annou... |
| | | 10/01/07 | Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for PYY3-36 Nasal Spray to Treat Obesity| BOTHELL, Wash., Oct. 1 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today the start of a Phase 2 clinical trial evaluating the Company's PYY3-36 Nasal Spray in obese patients. The study will enroll approximately 500 obese patients for a six-month, randomized, placebo-controlled dose ranging study with weight loss as the primary endpoint.
The Phase 2 study design will evaluate three different doses of Nastech's PYY3-36 Nasal Spray compared to placebo ... |
| | | 09/26/07 | Nastech to Host 2007 Analyst and Institutional Investor Day| BOTHELL, Wash., Sept. 26 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) will be hosting an analyst and institutional
investor day in New York City on Thursday, October 4, 2007 from 12:00 p.m. -
3:00 p.m. Eastern Time at the Westin New York at Times Square, on 270 West
43rd Street. The luncheon event will feature a presentation from Steven C.
Quay, M.D., Ph.D., Chairman, President and Chief Executive Officer and Gordon
Brandt, M.D., Executive Vice President... |
| | | 09/26/07 | Nastech Pharmaceutical Company Announces Initiation of Phase 2 Clinical Trial for Insulin Nasal Spray to Treat Diabetes| - Rapid-Acting, Non-Invasive Nasal Spray Dosage form is Patient Friendly and
Avoids Potential Safety Concerns of Pulmonary Delivery -
BOTHELL, Wash., Sept. 26 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today the start of a Phase 2 clinical
trial evaluating the Company's rapid-acting Insulin Nasal Spray in
approximately 20 patients with type 2 diabetes. The study is a randomized,
crossover study evaluating formulations of Insulin ... |
| | | 09/20/07 | Nastech to Present at UBS Global Life Sciences Conference| BOTHELL, Wash., Sept. 20 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it will present at the UBS
Global Life Sciences Conference on Wednesday, September 26, 2007 at 12:00 p.m.
Eastern Time at the Grand Hyatt in New York City.
To access the live audio webcast for this conference, please log on to
Nastech's website at http://www.nastech.com approximately 15 minutes prior to
the presentation in order to register and download any nec... |
| | | 08/08/07 | Nastech Announces Second Quarter 2007 Financial Results| BOTHELL, Wash., Aug. 8 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today reported financial results for the three-
and six-month periods ended June 30, 2007.
Revenue for the three months ended June 30, 2007 was $4.9 million,
compared to $11.4 million for the three months ended June 30, 2006. The 2006
period included revenue of $10.8 million related to our Parathyroid Hormone
(PTH1-34) nasal spray collaboration with Procter & Gamble Pharmaceuticals,... |
| | | 08/06/07 | Nastech Pharmaceutical Company to Host Webinar on its Strategy for Development of RNAi Therapeutics for Treatment of Influenza| Presented by Steven Quay, M.D., Ph.D., Chairman, President and CEO of Nastech,
and Michael Templin, Ph.D., Director of Pharmacology and Toxicology
BOTHELL, Wash., Aug. 6 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) will host a Webinar to discuss the Company's novel
approach for the development of small interfering RNA (siRNA) therapeutics for
treatment of influenza. Details follow:
What: Webinar discussing the approach of using siRNAs that ta... |
| | | 08/01/07 | Nastech to Release Second Quarter Financial Results and Host Webcast on Wednesday, August 8, 2007| BOTHELL, Wash., Aug. 1 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that its second quarter financial
results will be released on Wednesday, August 8, 2007 after the Nasdaq Global
Market System closes. Management will host a conference call with investors
and financial analysts to discuss these results and to provide an update of
the Company's clinical pipeline at 4:30 p.m. Eastern Time (1:30 p.m. Pacific
Time).
To participate in the... |
| | | 07/17/07 | Nastech Pharmaceutical Company Announces Issuance of Patents for Parathyroid Hormone Nasal Spray for Osteoporosis and PYY Nasal Spray for Obesity| BOTHELL, Wash., July 17 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today the issuance of two U.S. patents
by the U.S. Patent and Trademark Office. The patents relate to the Company's
Parathyroid Hormone Nasal Spray for treatment of osteoporosis, No. 7,244,709,
titled "Compositions and Methods for Enhanced Mucosal Delivery of Parathyroid
Hormone," and PYY Nasal Spray for treatment of obesity, No. 7,244,412, titled
"Methods for Manipulating Upp... |
| | | 06/12/07 | Nastech Announces Issuance of a U.S. Patent for Nascobal(R) Nasal Spray| Triggers $2 Million Milestone Payment from QOL Medical
BOTHELL, Wash., June 12 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today the issuance of a U.S. patent, No.
7,229,636, from the U.S. Patent and Trademark Office, titled "Cyanocobalamin
Low Viscosity Aqueous Formulations for Intranasal Delivery." Issuance of this
patent triggers an obligation by QOL Medical LLC to pay Nastech a $2 million
milestone under the license agreement g... |
| | | 06/07/07 | Nastech to Present at Needham & Company Biotechnology & Medical Technology Conference| BOTHELL, Wash., June 7, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it will present at the
Needham & Company Biotechnology & Medical Technology Conference on Thursday,
June 14, 2007 at 8:30 a.m. Eastern Time at the New York Palace Hotel in New
York City.
To access the live audio webcast for this conference, please log on to
Nastech's website at http://www.nastech.com approximately 15 minutes prior to
the pr... |
| | | 05/25/07 | Nastech to Present at Friedman Billings Ramsey Growth Conference| BOTHELL, Wash., May 25 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it will present at the
Friedman Billings Ramsey Growth Conference on Wednesday, May 30, 2007 at 11:15
a.m. Eastern Time at the Grand Hyatt in New York City.
To access the live audio webcast for this conference, please log on to
Nastech's website at http://www.nastech.com approximately 15 minutes prior to
the presentation in order to register and download any nece... |
| | | 05/07/07 | Nastech Announces First Quarter 2007 Financial Results| BOTHELL, Wash., May 7 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today reported financial results for the quarter
ended March 31, 2007.
Revenue for the three months ended March 31, 2007 was $5.0 million,
compared to $6.7 million for the three months ended March 31, 2006. The 2007
period included recognition of reimbursement revenue related to Nastech's
Parathyroid Hormone (PTH 1-34) nasal spray collaboration with Procter & Gamble
Pharmaceuticals,... |
| | | 05/03/07 | Nastech to Present at Acumen BioFin Rodman & Renshaw Global Healthcare Conference|
UPDATE: NASTECH WILL NOT BE PRESENTING AT THIS CONFERENCE
BOTHELL, Wash., May 3 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it will present at the Acumen
BioFin Rodman & Renshaw Global Healthcare Conference on Monday, May 14, 2007
at 9:25 a.m. Central European Summer Time (3:25 a.m. Eastern Daylight Time) at
the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.
To access the live audio webcast for this conference, pl... |
| | | 05/01/07 | Nastech to Present at UBS Global Generic and Specialty Pharmaceuticals Conference| BOTHELL, Wash., May 1 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it will present at the UBS
Global Generic and Specialty Pharmaceuticals Conference on Wednesday, May 9,
2007 at 10:00 a.m. Eastern Time at the Grand Hyatt in New York City.
To access the live audio webcast for this conference, please log on to
Nastech's website at http://www.nastech.com approximately 15 minutes prior to
the presentation in order to register and do... |
| | | 04/26/07 | Nastech to Release First Quarter Financial Results and Host Webcast on Monday, May 7, 2007| BOTHELL, Wash., April 26 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that its first quarter financial
results will be released on Monday, May 7, 2007 after the Nasdaq National
Market System closes. Management will host a conference call with investors
and financial analysts to discuss these results and to provide an update of
the Company's clinical pipeline at 4:30 p.m. Eastern Time (1:30 p.m. Pacific
Time).
To participate in the l... |
| | | 03/16/07 | Nastech to Present at Invest Northwest Investor and CEO Forum| BOTHELL, Wash., March 16 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it will present at the Invest
Northwest Investor and CEO Forum on Tuesday, March 20, 2007 at 4:35 p.m.
Pacific Time at the Bell Harbor International Conference Center in Seattle.
To access the live audio webcast for this conference, please log on to
Nastech's website at http://www.nastech.com approximately 15 minutes prior to
the presentation in order to regi... |
| | | 03/07/07 | Nastech Announces Fourth Quarter and Full Year 2006 Financial Results| BOTHELL, Wash., March 7 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK), today reported financial results for the fourth
quarter and year ended December 31, 2006.
Revenue for the three months ended December 31, 2006 was $4.8 million,
compared to revenue of $1.3 million for the 2005 period. Revenue for the year
ended December 31, 2006 was $28.5 million, compared to $7.4 million for the
2005 period. The increase in revenue for the full year was due to inc... |
| | | 02/23/07 | Nastech to Release Fourth Quarter and Full Year 2006 Financial Results and Host Webcast on Wednesday, March 7, 2007| BOTHELL, Wash., Feb. 23 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that its fourth quarter and full
year 2006 financial results will be released on Wednesday, March 7, 2007 after
the Nasdaq National Market System closes. Management will host a conference
call with investors and financial analysts to discuss these results and to
provide an update of the Company's clinical pipeline at 4:30 p.m. Eastern Time
(1:30 p.m. Pacific Time).
... |
| | | 02/07/07 | Nastech to Present at BIO CEO & Investor Conference| BOTHELL, Wash., Feb. 7 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it will present at the BIO
CEO & Investor Conference on Tuesday, February 13, 2007 at 12:00 p.m. Eastern
Time at The Waldorf-Astoria Hotel in New York City.
To access the live audio webcast for this conference, please log on to
Nastech's website at http://www.nastech.com approximately 15 minutes prior to
the presentation in order to register and download any nece... |
| | | 01/18/07 | Nastech Announces Pricing of Common Stock Offering| BOTHELL, Wash., Jan. 18 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today announced the pricing of an underwritten
public offering of 3.25 million shares of its common stock at an estimated
total public offering price of up to approximately $42.9 million. The
offering is being made pursuant to a shelf registration that became effective
on November 29, 2006. All of the shares are being sold by Nastech. UBS
Investment Bank acted as sole bookrunner for... |
| | | 12/21/06 | Nastech Reports Positive PYY Nasal Spray Clinical Trial Data and Will Advance Obesity Clinical Program in 2007| Trial Demonstrates Both Intravenous and PYY Nasal Spray
Produce Satiety and Calorie Reduction
BOTHELL, Wash., Dec. 21 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today reported positive results from a dose
ranging study designed to evaluate the pharmacokinetic parameters, appetite,
food intake and safety of various doses of Nastech's proprietary PYY(3-36)
nasal spray in obese subjects. The study identified doses for a long... |
| | | 12/06/06 | Nastech Announces Positive Phase 1 Clinical Results of Insulin Nasal Spray Compared to Exubera(R) Inhalation Powder and NovoLog(C) Insulin Aspart Injection| Study shows Insulin Nasal Spray provides the fastest insulin response which
may be especially useful for type 2 diabetic patients
BOTHELL, Wash., Dec. 6 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today announced results from a placebo controlled,
dose-escalation, cross-over Phase 1 study of Nastech's proprietary insulin
nasal spray formulations, NovoLog insulin aspart (rDNA origin) injection and
Exubera (insulin human [rDNA origin]) Inhala... |
| | | 12/04/06 | Nastech Pharmaceutical Company Inc. Provides Update on Parathyroid Hormone (PTH1-34) Nasal Spray for Treatment of Osteoporosis| BOTHELL, Wash., Dec. 4 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) today provided a progress report on the
significant clinical development program currently being conducted and planned
for the Parathyroid Hormone (PTH1-34) Nasal Spray, which is under development
for the treatment of osteoporosis. Nastech also provided information with
regard to an amendment to the contract with Procter & Gamble Pharmaceuticals,
Inc., a division of The Procter &... |
| | | 12/04/06 | Nastech to Present at BMO Capital Markets Focus on Healthcare Conference| BOTHELL, Wash., Dec. 4 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) announced today that it will present at the BMO
Capital Markets Focus on Healthcare Conference on Wednesday, December 6, 2006
at 1:30 p.m. Eastern Time at the Millennium Broadway Hotel in New York City.
To access the live audio webcast for this conference, please log on to
Nastech's website at http://www.nastech.com approximately 15 minutes prior to
the presentation in order to reg... |
| | | 11/08/06 | Nastech RNAi Webinar Scheduled for Thursday, November 9, 2006, at 10:30 a.m. Eastern Time| Emerging RNAi Therapeutics Programs and Delivery Technology to be
Presented by Steven C. Quay, M.D., Ph.D., Chairman, President and CEO
BOTHELL, Wash., Nov. 8 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical
Company Inc. (Nasdaq: NSTK) will be hosting a Webinar to discuss the science
of RNA interference (RNAi), its emerging siRNA therapeutics programs and siRNA
drug delivery technology. Details follow:
What: Webinar on the science of RNAi and the Company's RNAi ... |
| | | 11/08/06 | Nastech Licenses RNAi Intellectual Property and Technology from City of Hope| Novel Dicer-Substrate RNAi Technology Could Offer Increased Potency
for Drug Development as Compared to Conventional RNAi Technology
BOTHELL, Wash. and DUARTE, Calif., Nov. 8 /PRNewswire-FirstCall/ --
Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that it has
entered into a license agreement with City of Hope for rights to Dicer-
Substrate RNA interference (RNAi) intellectual property and technology.
Nastech obtained exclusive rights to five undisclo... |
| | | 11/02/06 | |
|
|
|
